Javier A. Andres Jaimes

Dr. Javier A. Andres Jaimes

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2020 in Antiviral Research
Verified
Journal Article
Closed access
TTTiffany Tang
Tiffany Tang
MBMiya Bidon
Miya Bidon
JJJavier A. Andres Jaimes
Javier A. Andres Jaimes
GWGary R. Whittaker
Gary R. Whittaker
SDSusan Daniel
Susan Daniel

1 May 2020 in Journal of Molecular Biology
Verified
Journal Article
Closed access
JJJavier A. Andres Jaimes
Javier A. Andres Jaimes
NANicole M. André
Nicole M. André
JCJoshua S. Chappie
Joshua S. Chappie
JMJean Millet
Jean Millet
GWGary R. Whittaker
Gary R. Whittaker

1 June 2020 in iScience
Verified
Journal Article
Open access
JJJavier A. Andres Jaimes
Javier A. Andres Jaimes
JMJean Millet
Jean Millet
GWGary R. Whittaker
Gary R. Whittaker
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 19 (COVID-19) has rapidly spread to the entire world within a few months. The origin of SARS-CoV-2 has been related to the lineage B Betacoronavirus SARS-CoV and SARS-related coronaviruses found in bats. Early characterizations of the SARS-CoV-2 genome revealed the existence of a distinct four amino acid insert within the spike (S) protein (underlined, SPRRAR↓S), at the S1/S2 site located at the interface between the S1 receptor binding subunit and the S2 fusion subunit. Notably, this insert appears to be a distinguishing feature among SARS-related sequences and introduces a potential cleavage site for the protease furin. Here, we investigate the potential role of this novel S1/S2 cleavage site and present direct biochemical evidence for proteolytic processing by a variety of proteases. We discuss these findings in the context of the origin of SARS-CoV-2, viral stability, and transmission.

10 December 2021 in iScience
Verified
Journal Article
Open access
BLBailey Lubinski
Bailey Lubinski
MFMaureen H.V. Fernandes
Maureen H.V. Fernandes
LFLaura Frazier
Laura Frazier
TTTiffany Tang
Tiffany Tang
SDSusan Daniel
Susan Daniel
GWGary R. Whittaker
Gary R. Whittaker
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the agent causing the COVID-19 pandemic. SARS-CoV-2 B.1.1.7 (Alpha), a WHO variant of concern first identified in the United Kingdom in late 2020, contains several mutations including P681H in the spike S1/S2 cleavage site, which is predicted to increase cleavage by furin, potentially impacting the viral cell entry. Here, we studied the role of the P681H mutation in B.1.1.7 cell entry. We performed assays using fluorogenic peptides mimicking the Wuhan-Hu-1 and B.1.1.7 S1/S2 sequence and observed no significant difference in furin cleavage. Functional assays using pseudoparticles harboring SARS-CoV-2 spikes and cell-to-cell fusion assays demonstrated no differences between Wuhan-Hu-1, B.1.1.7, or a P681H point mutant. Likewise, we observed no differences in viral growth between USA-WA1/2020 and a B.1.1.7 isolate in cell culture. Our findings suggest that, although the B.1.1.7 P681H mutation may slightly increase S1/S2 cleavage, this does not significantly impact viral entry or cell-cell spread.

12 January 2021 in ACS Infectious Diseases
Verified
Journal Article
Closed access
TTTiffany Tang
Tiffany Tang
JJJavier A. Andres Jaimes
Javier A. Andres Jaimes
MBMiya K. Bidon
Miya K. Bidon
MSMarco R. Straus
Marco R. Straus
SDSusan Daniel
Susan Daniel
GWGary R. Whittaker
Gary R. Whittaker

10 January 2020 in Viruses
Verified
Journal Article
Open access
PDF file
JJJavier A. Andres Jaimes
Javier A. Andres Jaimes
JMJean Millet
Jean Millet
ASAlison Stout
Alison Stout
NANicole Andre
Nicole Andre
GWGary R. Whittaker
Gary R. Whittaker
Feline coronavirus (FCoV) is a complex viral agent that causes a variety of clinical manifestations in cats, commonly known as feline infectious peritonitis (FIP). It is recognized that FCoV can occur in two different serotypes. However, differences in the S protein are much more than serological or antigenic variants, resulting in the effective presence of two distinct viruses. Here, we review the distinct differences in the S proteins of these viruses, which are likely to translate into distinct biological outcomes. We introduce a new concept related to the non-taxonomical classification and differentiation among FCoVs by analyzing and comparing the genetic, structural, and functional characteristics of FCoV and the FCoV S protein among the two serotypes and FCoV biotypes. Based on our analysis, we suggest that our understanding of FIP needs to consider whether the presence of these two distinct viruses has implications in clinical settings.